SCHEMBL2760428

SCHEMBL2760428

Nc1cccc(-c2nc3nc(CN4CCNCC4)ccc3o2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.49
KDM4E B2RXH2 5/20 0.46
RAB9A P51151 5/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
ALDH1A1 P00352 3/20 0.46
KMT2A Q03164 3/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 2/20 0.46
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
CXCR4 P61073 3/20 0.43
GAA P10253 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
CHRM3 P20309 1/20 0.39
TP53 P04637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PRMT5 O14744 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL219507 0.78 GPR119 (0.43) NPC1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL13470749 0.78 NPC1 (0.59) NPC1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL219440 0.75 NPC1 (0.55) NPC1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL2740248 0.74 JAK3 (0.51) NPC1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL13253246 0.73 JAK3 (0.44) NPC1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL4698674 0.72 NPC1 (0.53) NPC1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL220096 0.71 NPC1 (0.63) NPC1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL465722 0.67 CXCR4 (0.65) KMT2AMEN1CXCR4
SCHEMBL31631307 0.67 NPC1 (1.00) NPC1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL221887 0.67 NPC1 (1.00) NPC1KDM4ERAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022254-A1 SIRTUIN MODULATING COMPOUNDS SIRTRIS PHARMACEUTICALS, INC. (US) 2012-01-26 US disclosed
US-8088928-B2 Sirtuin modulating compounds SIRTRIS PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8044198-B2 Sirtuin modulating compounds SIRTRIS PHARMACEUTICALS, INC. (US) 2011-10-25 US disclosed
US-20090099170-A1 Sirtuin modulating compounds SIRTRIS PHARMACEUTICALS, INC. (US) 2009-04-16 US disclosed
US-7345178-B2 Sirtuin modulating compounds SIRTRIS PHARMACEUTICALS, INC. (US) 2008-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099170-A1 Sirtuin modulating compounds SIRT1, SIRT3, SIRT2 NPC1 3399/4885KDM4E 1599/4885RAB9A 965/4885
US-20120022254-A1 SIRTUIN MODULATING COMPOUNDS SIRT1, SIRT3, SIRT2 NPC1 3399/4885KDM4E 1599/4885RAB9A 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.